From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)
 | RF- poly JIA (n=171) | RF+ poly JIA (n=30) | Oligo JIA (n=243) | Other JIA (n=161) |
---|---|---|---|---|
Time (year) from diagnosis to 1st DMARD | 0.01 (0, 0.09) | 0.01 (0, 0.05) | 0.31 (0.07, 1.21) | 0.04 (0, 0.13) |
cJADAS | 16 (10.5, 20.5) | 19 (15.5, 25) | 7 (5, 10) | 11 (7.5, 15) |
AJC | 8 (4, 10) | 10 (7, 10) | 1 (1, 2) | 2 (1, 6) |
Patient global | 4 (2, 6) | 5.5 (3, 7) | 3 (1, 5) | 4 (2, 6) |
PGA | 4 (2.5, 7) | 5.5 (3, 8) | 3 (1, 4) | 3 (1.5, 5) |
Joint injection | 37 (22%) | 9 (30%) | 106 (44%) | 41 (25%) |
Glucocorticoids | 80 (47%) | 20 (67%) | 68 (28%) | 48 (30%) |
nbDMARD >6 months | 133 (78%) | 23 (77%) | 89 (37%) | 79 (49%) |
bDMARD >6 months | 91 (53%) | 20 (67%) | 46 (19%) | 82 (51%) |